Fractyl Health (NASDAQ:GUTS) Stock Price Target Lowered at Morgan Stanley

Fractyl Health (NASDAQ:GUTS) had its target price lowered by Morgan Stanley to $4.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price objective would suggest a potential upside of 189.86% from the company’s previous close.

GUTS has been the topic of several other research reports. Craig Hallum set a $5.00 price target on shares of Fractyl Health in a research note on Monday. Wall Street Zen downgraded shares of Fractyl Health from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings cut shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $50.25.

Fractyl Health Price Performance

Shares of NASDAQ:GUTS traded down $0.17 during trading on Monday, reaching $1.38. The company had a trading volume of 1,131,434 shares, compared to its average volume of 330,602. The company has a current ratio of 3.15, a quick ratio of 3.15 and a debt-to-equity ratio of 1.41. Fractyl Health has a 12 month low of $1.37 and a 12 month high of $29.34. The stock has a market capitalization of $18.30 million, a P/E ratio of -0.13 and a beta of 2.42. The company has a fifty day moving average of $6.75 and a two-hundred day moving average of $8.03.

Fractyl Health (NASDAQ:GUTS) last announced its earnings results on Monday, August 10th. The company reported ($1.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.62) by $0.18. Equities research analysts forecast that Fractyl Health will post -6.32 earnings per share for the current year.

Institutional Investors Weigh In On Fractyl Health

A number of institutional investors have recently bought and sold shares of GUTS. Sanctuary Advisors LLC bought a new position in shares of Fractyl Health during the second quarter worth $26,000. Accredited Investors Inc. purchased a new position in Fractyl Health during the 1st quarter valued at approximately $46,000. FNY Investment Advisers LLC increased its stake in Fractyl Health by 84.3% in the 2nd quarter. FNY Investment Advisers LLC now owns 65,420 shares of the company’s stock worth $51,000 after acquiring an additional 29,920 shares during the last quarter. PEAK6 LLC purchased a new stake in Fractyl Health during the second quarter valued at $159,000. Finally, BlackRock Inc. purchased a new position in shares of Fractyl Health in the 2nd quarter worth $1,431,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including type 2 diabetes and obesity. The company’s approach is based on targeting the biology of the gastrointestinal system and developing treatments intended to address underlying disease mechanisms rather than relying solely on chronic medication.

Fractyl Health’s lead product candidate is Revita, an investigational, minimally invasive endoscopic procedure designed to resurface the duodenal lining.